Endothelin Expression and the Progression of Heart Failure
Open Access
- 20 January 2004
- journal article
- editorial
- Published by Wolters Kluwer Health in Circulation
- Vol. 109 (2) , 143-145
- https://doi.org/10.1161/01.cir.0000110644.92116.91
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 2003
- Hemodynamic and Neurohumoral Effects of Selective Endothelin A (ET A ) Receptor Blockade in Chronic Heart FailureCirculation, 2002
- Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart FailureCirculation, 2002
- Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?International Journal of Cardiology, 2002
- Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trialThe Lancet, 2001
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF)The Lancet, 1999
- Inhibition of myocardial endothelin pathway improves long-term survival in heart failureNature, 1996
- Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection FractionsNew England Journal of Medicine, 1992